Our
Science
Our pioneering LYTAC (Lysosomal Targeting Chimera) Platform enables targeted degradation of extracellular proteins. We are leveraging the flexibility of our platform to pursue targets previously considered undruggable, opening the potential for new therapeutics options for patients.